Revefenacin
- TRADE NAME: Yupelri (Theravance Biopharma)
- INDICATIONS: indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
- CLASS: Anticholinergic
- HALF-LIFE: 22–70 hours
FDA APPROVAL DATE: 11/09/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:PREGNANCY CATEGORY: N/A
No adequate studies conducted. Advised to contact physician if pregnancy occurs while taking drug.
Please login to see the rest of this drug profile
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric